Noninvasive prenatal testing (NIPT) is also known as noninvasive prenatal diagnosis (NIPD). Non-invasive prenatal testing (NIPT) is used for screening pregnant women at high risk of developing fetal chromosomal aneuploidies such as trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome) or a sex chromosome irregularity, such as Turner syndrome. The testing can also be used to determine a baby's sex and rhesus (Rh) blood type. The Non-Invasive Prenatal Test (NIPT) is a DNA test on maternal blood to screen for the fetal aneuploidies (chromosomes 21, 18, 13) during pregnancy. Now, noninvasive prenatal testing is only available for women who have certain risk issue. Non-invasive prenatal testing (NIPT) offers harmony, verifi, Panorama, informaSeq, VisibiliT, PrenaTest, BambniTest and other test.

The NIPT market is growing, due to rising healthcare expenditure. The common maternal age is rising in high income countries, owing to varying pattern of employment, education and marriage and growing price of raising a child. The increase in common maternal age is resulting in the development of the global NIPT market. The exponential growth of the NIPT market is supported by factors such as high birth rate with Down syndrome, no risk of miscarriage with NIPT, and shifting trend toward child bearing at advanced maternal age.

Get free sample research report at http://www.syndicatemarketresearch.com/request-for-sample.html?flag=S&repid=50313

The report includes detailed competitive landscape of the global Non-Invasive Prenatal Test market and an analysis of Porter’s five forces model for the Non-Invasive Prenatal Test market has also been included. It includes company market share analysis, product portfolio of the major industry participants. The report provides detailed segmentation of the Non-Invasive Prenatal Test market based on Test and region segment. Bambni test, harmony, informaSeq, materniT21 PLUS, NIFTY, panorama, PrenaTest, verifi, VisibiliT is the Test of Non-Invasive Prenatal Test market. MaterniT21 PLUS was the most conventional test in the market and led the total market.

Major regional segments analyzed in this study include North America, Europe, Asia Pacific, Latin America, and Middle East and Africa with its further bifurcation into major countries including U.S., Germany, France, UK, China, Japan, India, and Brazil. This segmentation includes demand for Non-Invasive Prenatal Test based on individual products and applications in all the regions and countries. The market is expected to be driven by the demand from untapped regions such as Europe and Asia Pacific during the forecast period.

Get inquiry report before buying at http://www.syndicatemarketresearch.com/market-analysis/noninvasive-prenatal-testing-nipt-market.html#inquiry-for-buying

The report covers detailed competitive outlook including company profiles of the key participants operating in the global market. Key players profiled in the report include Sequenom Inc., BGI, LabCorp, LifeCodexx AG, Natera Inc., Quest Diagnostics Incorporated, Illumina Inc., Berry Genomics, Ariosa Diagnostics and Hoffmann-La Roche Ltd.

Noninvasive Prenatal Testing (NIPT) Market: Test Segment Analysis

Harmony
InformaSeq
Bambni Test
MaterniT21 PLUS
NIFTY
PrenaTest
VisibiliT
Verifi
Others
Noninvasive Prenatal Testing (NIPT) Market: Regional Segment Analysis

North America
U.S.
Europe
Germany
France
UK
Asia Pacific
China
Japan
India
Latin America
Brazil
Middle East And Africa
Browse the full report at http://www.syndicatemarketresearch.com/market-analysis/noninvasive-prenatal-testing-nipt-market.html

Contact US:

Joel John
33442 SW 15 Street,Suit #8138
Deerfield Beach,Florida 33442
United States
Toll Free: +1-855-465-4651 (USA-CANADA)
Tel: +1-386-310-3803
Email: [email protected]

Website:http://www.syndicatemarketresearch.com/